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Abstract
We fabricated a novel vascular endothelial growth factor (VEGF)-loaded poly(lactic-co-glycolic acid) (PLGA)-
nanoparticles (NPs)-embedded thermo-sensitive hydrogel in porcine bladder acellular matrix allograft (BAMA)
system, which is designed for achieving a sustained release of VEGF protein, and embedding the protein carrier
into the BAMA. We identified and optimized various formulations and process parameters to get the preferred
particle size, entrapment, and polydispersibility of the VEGF-NPs, and incorporated the VEGF-NPs into the (poly
(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (Pluronic
®) F127 to achieve the preferred VEGF-NPs
thermo-sensitive gel system. Then the thermal behavior of the system was proven by in vitro and in vivo study,
and the kinetic-sustained release profile of the system embedded in porcine bladder acellular matrix was
investigated. Results indicated that the bioactivity of the encapsulated VEGF released from the NPs was reserved,
and the VEGF-NPs thermo-sensitive gel system can achieve sol-gel transmission successfully at appropriate
temperature. Furthermore, the system can create a satisfactory tissue-compatible environment and an effective
VEGF-sustained release approach. In conclusion, a novel VEGF-loaded PLGA NPs-embedded thermo-sensitive
hydrogel in porcine BAMA system is successfully prepared, to provide a promising way for deficient bladder
reconstruction therapy.
Introduction
A variety of congenital and acquired conditions cause
compromised bladder capacity and compliance. The
major surgical solution is enterocystoplasty, whereby the
functionally deficient bladder is reconstructed using bio-
materials. In terms of biomaterials for bladder recon-
struction, bladder acellular matrix allograft (BAMA)
[1,2] has great potential for complete and functional
regeneration of the bladder. BAMA is a naturally
derived biodegradable material that is currently being
developed for use as a bladder substitute. It is produced
by extracting the cells and soluble matrix components
from the extracellular matrix, and so it has almost all
the properties of a normal bladder, and maintains a low
potential for inflammatory attack on the graft because
most of the antigenic proteins are extracted from the
bladder tissue. The long-term follow-up of vascular acel-
lular matrix allografts has demonstrated their biocom-
patibility [3-5].
Previous research has proven that the administration
of growth factors can promote tissue revascularization.
Under an appropriate dosage, pro-angiogenic cytokines,
such as vascular endothelial growth factor (VEGF) [6,7],
can up-regulate angiogenesis by signaling vascular
endothelial cells to undergo proliferation, migration, and
differentiation into new blood vessels. However, the
short-lived effect and high instability (such as oxidation,
deamidation, and diketopiperazine formation in a
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provided the original work is properly cited.physiological environment) of the VEGF protein result
in some disappointing clinical trials, because the thera-
peutic effects of the protein can only be achieved at
extremely high doses, which often results in side effects
such as the progression of malignant vascular tumors
[8]. A superior formulation is needed to deliver VEGF
continuously to maintain the VEGF concentration
within the therapeutic window during the long term of
tissues’ reconstruction.
In this study, we report a novel VEGF-loaded nano-
particles (NPs)-embedded porcine bladder acellular
matrix with thermo-response system, which is designed
for achieving a sustained release of VEGF protein, and
embedding the protein carrier into the BAMA. For the
incorporation and sustained release of VEGF, the pro-
tein was encapsulated in NPs with biodegradable poly
(lactic-co-glycolic acid) (PLGA) by multi-emulsion and
solvent evaporation methods, which result in the pro-
tein-loaded round-shaped NPs [9,10]. Then, the VEGF-
loaded PLGA NPs are combined with a hydrophilic gel
matrix, (poly(ethylene oxide)-poly(propylene oxide)-poly
(ethylene oxide) (Pluronic
®) F127 hydrogel [11], using
the sol-gel transition to give a well-dispersed PLGA par-
ticles-embedded hydrogel [1 2 ] .F i n a l l y ,t h eV E G F - N P s -
F127 gel was embedded in BAMA with multipoint injec-
tion. Such a strategy as this allows the carrier system to
show a sustained release of protein, a retention of pro-
tein-loaded NPs in BAMA, as well as additional proper-
ties such as thermo-sensitivity and biocompatibility.
Experimental
Materials
Pluronic
® F127 triblock copolymer, Tween
® 80 (polyox-
yethylene sorbitan monooleate), and poly(vinyl alcohol)
(PVA) (Mw 14-16 kDa) were purchased from Sigma-
Aldrich (Shanghai, China). PLGA with a monomer ratio
(lactic acid/glycolic acid) of 50:50 was purchased from
Daigang Biomaterial Co., Ltd. (Jinan, China). rhVEGF165
and rhVEGF enzyme-linked immunosorbent assay
(ELISA) kit was purchased from Peprotech (Rocky Hill,
NJ, USA), and all other reagents were purchased from
Sigma-Aldrich.
Preparation of NPs-embedded thermo-sensitive hydrogel
PLGA NPs containing VEGF (0.1 μg/mg of NPs) were
prepared by the double emulsion-solvent evaporation
technique based on the method of Liao et al. [13]. In
briefly, 20 mg of PLGA was dissolved in appropriate
amount of dichloromethane. This polymer solution was
injected into 100 μL of phosphate-buffered saline, pH7.4
(PBS7.4) as the inner aqueous phase (W1) containing
VEGF, heparin (Hp, 16 kDa), and human serum albu-
min (HSA) (VEGF/Hp/HSA 1:1:500, w/w/w). Next,
the previously formed inner emulsion (W1/O) was
generated by a high-speed homogenizer of IKA ultra
turrax operating at 3,000 rpm for 2 min. Then, the first
emulsion was injected into 10 mL outer aqueous phase
(W2), which was composed of aqueous 1.5% (w/v) PVA
and 2% Tween80, resulting in a multiple emulsion (W1/
O/W2), which was homogenized by ultra turrax at spe-
cific speed and time following an incubation on ice.
This emulsion was put on a rota-evaporator under
vacuum (500 mHg) for 3 h at room temperature for
complete solvent evaporation. The organic phase was
evaporated leading to precipitation of polymer to get the
NPs, which hardens over time. The NPs were collected
by centrifugation at 10,000 × g for 5 min at 4°C and
washed with distilled water three times followed by
freeze-drying using mannitol as cryoprotectant (PLGA:
Mannitol:100:30) to get dry powder containing NPs.
In this process, several factors impact the formation of
NPs with acceptable size, polydispersity, and good
entrapment efficiency. Based on preliminary studies,
under the premise of specific PLGA and external aqu-
eous phase stabilizer, three critical factors, namely,
volume ratio of organic solvent phase to external aqu-
eous phase, agitation speed, and duration of homogeni-
zation were selected for the optimization of mean
particle size and entrapment efficiency. During the opti-
mization trials, these values for critical factors were var-
ied between the extreme levels. In the present design,
15 different experiments were carried out to identify the
optimum level of the major variables as indicated in
Table 1.
Fluorescent probes-loaded NPs were obtained by add-
ing hydrophilic CdTe quantum dots (QDs) (1 μg/mg of
NPs, prepared according to our previous report with
maximum emission wavelength of 590 nm) [14] into the
inner aqueous phase instead of VEGF protein, and the
NPs prepared as described produced optimized results.
The NPs containing only Hp and HSA were produced
as negative control.
Then, the accurate NPs (lyophilized) were resus-
pended in distilled water. This suspension was added to
the concentrated F127 solution so that the final F127
concentration reached 25% w/v and stirred gently for 10
min after incubation on ice for uniform distribution of
NPs in the F127 solution.
NPs morphology and particle size
The formulations prepared by double emulsification sol-
vent evaporation were performed for shape and surface
morphology using a Zeiss Ultra 55 scanning electron
microscope (SEM). The dried NP samples were sus-
pended in distilled water until further examination.
Particle diameter was determined using a Nicomp
380ZLS particle sizing system. Accordingly, the dried
NP samples were suspended in distilled water. The
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determine the mean diameter and polydispersity index.
Determination of encapsulation efficiency
The NP encapsulation efficiency (E.E.) was determined
upon their separation from the aqueous preparation
medium containing the non-associated protein by cen-
trifugation (20,000 × g,4 ° C ,1 0m i n ) .T h ea m o u n to f
free protein was determined in the supernatant using a
bicinchoninic acid assay. The extraction procedure was
performed for a total of 3 × for each particle type. The
NP E.E. was calculated using the following equation: E.
E. (%) = [(Total protein amount - Free protein amount)/
Total protein amount] × 100%.
Gelation temperature and thermo-reversible behavior in
vivo
The gelation temperatures of varying concentration (w/
v) of Pluronic F127 were determined by the tube inver-
sion method. In brief, accurate F127 was dissolved in
ultrapure water at cold temperature in Eppendorf tube,
the tubes were reversed constantly and the temperature
at which the solution stopped dropping was measured;
at this temperature, the solution was converted into gel.
The thermo-reversibility was verified by giving repeated
cooling and heating cycles to confirm any change in the
gelation temperature and reversibility of gel-sol
behavior.
To confirm the thermo-sensitive, sustained release
properties of the NPs-embedded hydrogel, physiologi-
cally normal nude mice were treated with QDs-NPs-
F127 gel, QDs-NPs, and QDs-physiological saline solu-
tion, and they were all treated with aliquots QDs dosage
of 2 mg/kg via subcutaneous injection. In vivo mouse
images were acquired using a Berthold Night OWL in
vivo imager. Fluorescence images of all the experimental
mice were taken continuously for 24 h along with the
typical images at 10 min post-injection.
Release kinetics
In vitro drug release of VEGF-loaded NPs-embedded
thermo-sensitive hydrogel was evaluated in buffer solu-
tion. In brief, 10 mg of dried NPs was suspended in 0.2
mL 25% Pluronic
® F127 solution, and then the solution
was rapidly pushed into a 2 cm
2 full-thickness porcine
bladder acellular matrix through multipoint sequential
injection. The matrix was dipped into 2 mL phosphate
buffer saline (PBS) at pH 7.4 and at 37°C, which had
previously been filtered on 0.22-μm sterile filters and
microbiologically preserved with 0.02%w/w sodium
azide. Then, the release media were placed in a thermo-
static bath at 37°C. At scheduled time intervals, the
release medium was withdrawn and replaced with the
equal volume of fresh, filtered medium. Release of
VEGF from NPs, 25% Pluronic
® F127, and NPs-
embedded 25% Pluronic
® F127 were tested at the same
time as references. Samples were centrifuged (20,000 ×
g, 4°C, 10 min), and the supernatant was analyzed for
VEGF content via ELISA using the VEGF ELISA kit as
per the manufacturer’s protocol. Results are expressed
as cumulative release of VEGF NPs ± SD (standard
deviation) of three replicates.
Bioactivity of released VEGF
The bioactivity of the VEGF released from the micro-
particles was evaluated in vitro by determining the
Table 1 Experimental design matrix with observed values of the objectives variables of protein-loaded NPs
Experiment Code X1 X2 X3 Z-Ave
a (nm) Polydispersibility Indice E.E.(%) ± SD (n =6 )
1 8.2 5 0.66 280.8 0.483 35.29 ± 0.07
2 8.2 5 0.24 309.5 0.286 38.82 ± 0.53
3 8.2 2 0.66 602.6 0.702 51.76 ± 0.28
4 8.2 2 0.24 1428.7 0.632 50.59 ± 0.46
5 5.5 6 0.45 291.2 0.378 48.82 ± 0.12
6 5.5 1 0.45 890.7 0.806 54.71 ± 0.09
7 5.5 3.5 0.8 355.4 0.567 42.94 ± 0.14
8 5.5 3.5 0.1 640.2 0.686 55.88 ± 0.10
9 2.8 5 0.66 337.0 0.492 44.12 ± 0.74
10 2.8 5 0.24 345.8 0.384 45.88 ± 0.67
11 2.8 2 0.66 651.0 0.712 50.00 ± 0.41
12 2.8 2 0.24 2503.5 0.762 52.35 ± 0.75
13 10 3.5 0.45 380.5 0.536 44.71 ± 0.69
14 1 3.5 0.45 1025.5 0.691 49.41 ± 0.21
15 5.5 3.5 0.45 429.2 0.555 47.06 ± 0.55
X1 represents duration of homogenization (min); X2 represents agitation speed (krpm); X3 represents volume ratio of organic solvent phase to external aqueous
phase (V/V); Z-Ave represents average particle size diameter; E.E. represents encapsulation efficiency.
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Page 3 of 8proliferative capacity of an endothelial cell line (human
umbilical vein endothelial cell, HUVEC) after VEGF
treatment. First, VEGF-loaded NPs were incubated in
Endothelial Cell Growth Medium-2 (EGM-2) without
growth factors for a continuous period of 1, 5, 10, or 15
days, the release EGM-2 medium was filtered with 0.22-
μm sterile filters and VEGF values were measured using
ELISA and stored at 4°C. Second, HUVEC were cultured
in EGM-2 media supplemented with 30 μg/mL endothe-
lial cell growth supplement, 10% fetal bovine serum, 1%
Hp, and 1% penicillin/streptomycin. In order to deter-
mine the endothelial cell proliferation capacity after
VEGF stimulation, the HUVEC were placed into 96-well
culture plates with a density of 1 × 10
3cells/well and
allowed to adhere overnight. Medium was then aspi-
rated, and the released EGM-2 medium supernatant
from VEGF-loaded NPs was then added to wells imme-
diately to make an equivalent final VEGF concentration
of 10 or 20 ng/mL. Native, non-encapsulated VEGF at
10 or 20 ng/mL was used as the 100% bioactivity bench-
mark, and wells with medium only (no VEGF), as well
as the released EGM-2 medium supernatant from non-
loaded NPs, were employed as the negative control.
Cells were incubated for 3 days, and the number of
viable cells in each experimental group was determined
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide assay.
Data presentation and statistical analyses
Unless otherwise indicated, data are represented as
mean ± SD. Statistical significance was determined
using a student’s t-test with a 95% confidence interval,
unless otherwise noted. Statistical calculations were per-
formed using a SPSS software.
Results and discussion
Preparation of NPs is a complex procedure as it
involves several processing variables and design com-
ponents [15,16]. Even slight changes of these variables
and system components can have significant impact on
the quality of final product. Unique attributes of NPs
such as particle size and entrapment efficiency are of
utmost importance from the biological and pharma-
ceutical point of view [17-19]. Particles with smaller
average diameter showed slower release. Smaller parti-
cles are generally formed with higher impact [20]. It
varies the tortuous polymeric diffusion pathways in
smaller particles [21]. This ultimately leads to a sus-
tained diffusion of protein from the particles. Another
quality attribute of NPs is the entrapment efficiency
which should be properly optimized to avoid the loss
of drug during processing [22]. It is of the highest
importance especially in case of drugs such as VEGF,
with their cost being very high. Here, we choose the
particle diameter and the entrapment efficiency as the
experimental investigation response. Using the double
emulsion method for preparation of NPs, the second
emulsification is decisive for the size of the NPs. Thus,
the intensity and the time of emulsification can be
used for controlling size. Here, we selected three criti-
cal factors, namely, volume ratio of organic solvent
phase to external aqueous phase, agitation speed, and
duration of homogenization for the optimization of the
experimental investigation response.
Table 1 depicts the various process parameters of the
prepared protein containing NPs. The results of the
particle size analysis by laser diffraction showed that
particle sizes varied from 280.8 to 2503.5 nm with vari-
able polydispersity indices among the experimental for-
mulations. Among them, formulation 1 had the least
value of the average diameter, whereas 12 had the maxi-
mum. The polydispersibility indices also showed the
similar patterns of dispersibilities, i.e., formulation 2 had
the least value and 6 had the maximum. The data sug-
gest that with increasing homogenizing speed, average
diameters of particles were reduced. However, when
speed of homogenization was further enhanced, the pro-
tein E.E. reduced too, Therefore, after all these results
having been considered, experiment 5 was concluded to
be the optimized one for the preparation of the protein-
loaded NPs.
The SEM study (Figure 1a) shows smooth, homoge-
neous, and spherical-shaped images in nano range, and
there is no aggregation after lyophilization in case of
experiment formulation code 5. Approximately more
than 90% particles were found to have diameter below
600 nm. The average particle size was about 300 nm,
and the densest and the narrowest range of particle dis-
persion was noticed between 100 and 400 nm.
The bioactivity of the encapsulated VEGF released
from the NPs was examined by determining its capacity
to induce proliferation of endothelial cells (HUVEC)
(Figure 2). VEGF-NPs (10 or 20 ng/mL) induced a 2-
2.5-fold increase in proliferation of HUVEC in compari-
son with control (no VEGF) or non-loaded NPs (NL-
NPs) after 3 days in culture (P < 0.01). This increase
was similar to that observed when HUVEC cells were
cultured with addition of free-VEGF at doses of 10 or
20 ng/mL. The results show NL-NPs caused little reduc-
tion in cell viability compared with the control, but
there was not any significant statistical difference
between them, indicating that NL-NPs were better toler-
ated at the experiment’s concentration. Furthermore,
similar levels of stimulation in the HUVEC cells treated
either with the free-VEGF or the VEGF-NPs were
detected, confirming that the process of encapsulation
does not affect negatively VEGF biological activity
significantly.
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Page 4 of 8It is noteworthy to mention again that an appropri-
ate sol-gel temperature, gelation, and maintaining of
its consistency after injection of the block copolymer
solution, were crucial for its utilization for various
applications. Tube inversion has been used previously
by several groups to determine the gel boundary of
gel-sol behavior [23]. Thermoreversible sol-gel transi-
tion of F127 aqueous solution originates from micelle
formation and micelle volume change owing to PEO/
water, and PPO/water’s lower critical solution tem-
perature (LCST) behavior [24]. Above LCST
temperature of PPO, the micelle with PPO core and
PEO shell appears. As temperature increases, the num-
ber of micelles increases. At high temperature, interac-
tion of PEO and water is unfavorable, and therefore,
gel-to-sol transition occurs because of dehydration and
shrinking of PEO shell. Above PEO-water LCST tem-
perature, phase separation between polymer and water
is observed. As illustrated in Figure 3, gelation tem-
perature decreased with increase of the concentration
of F127 and decreased proportionally to the concentra-
tion. Solutions containing less than 15.4% F127 did not
 (a)
(b) 
Figure 1 SEM images of NPs: (a) free NPs, and (b) NPs embedded in Pluronic F127 gel.
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Page 5 of 8form gels over the tested temperature range, while a
F127 concentration higher than 30% led to difficulty in
preparation and administration. In this study, approxi-
mately 25% of F127 was required to obtain NPs hydro-
gel formulation with the transition temperature of
approx. 20°C (Figure 4a, b).
Figure 5 exhibits the typical fluorescence images of
different healthy group mice from 10-min to 24-h post-
injection. Figure 5a represents the image of the mice
with QDs-NPs-F127 gel treatment on the right leg, and
bright fluorescence signal was observed at10 min; after
24 h, the intensity of the fluorescence signal did not
vanish. Obviously, this may possibly be due to the rapid
sol-gel transmission of the QDs-NPs-F127 gel. Further-
more, the shape of the injectant below the skin of the
mouse was maintained in smooth and clear condition
after 24 h, and the tissues around the injectant did not
induce any inflammatory reaction, representing the
superior biocompatibility of the QDs-NPs-F127 gel.
Figure 5b represents the fluorescence images of the
mice with QDs-NPs treatment; the images show that
the fluorescence signal was aggregated and weakened
rapidly after injection, the solvent of the injectant was
rapidly absorbed simultaneously, and the NPs were
compressed and degraded in accelerated manner. Figure
5c represents the images of the mice with QDs-physio-
logical saline solution, while a curious inflammatory
reaction, the swelling, and distension at the administra-
tion site were observed after 24 h of post-injection, and
this may be attributed to the serious toxicity of the
CdTe QDs.
The in vitro release kinetics was performed in PBS (pH
7.4) at 37°C for 60 days as reported in Figure 6. In this
study, VEGF released from NPs within the first 2 days
(burst effect) was 30 ± 3%, followed by a phase of sus-
tained release with almost 75% of VEGF being released
within 60 days. The VEGF release from NPs-F127 gel
embedded in full-thickness acellular porcine bladder
matrix (Figure 4c, d) was slower than that from VEGF-
NPs (almost 60% of VEGF being released within 60 days).
The burst effect was decreased below 15 ± 2%, which
might be due to longer diffusion pathways of VEGF in
porcine bladder acellular matrix. In addition, sustained
release of VEGF from simple F127 gel was not remark-
able compared with the two groups described above.
Conclusion
A thermo-sensitive hydrogel-entrapped VEGF-NPs sys-
tem has been prepared and characterized in this study.
Figure 2 Proliferation of HUVEC cells was induced by 10 ng/mL
free-VEGF, or 20 ng/mL free-VEGF, or 10 ng/mL VEGF in NPs,
or 20 ng/mL VEGF in NPs, or non-loaded NPs (NL-NPs) at the
same concentration of PLGA with the application described
above, and compared to culture medium alone (control) for 1-
5 days. Y-axis represents fold increase versus control. Asterisk
represents P < 0.05 and double asterisk represents P < 0.01.
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Figure 3 Gelation temperature and thermoreversible behavior
of Pluronic F 127 gel.
Figure 4 Gel-to-sol transition behavior of NPs-F127 solution. (a)
Solution state of 50 mg/mL NPs in 20% F127 (left) and in 25% F127
(right) at 15°C; (b) solution state of 50 mg/mL NPs in 20% F127
(left) and in 25% F127 (right) at 20°C; (c) an porcine bladder
acellular matrix; and (d) an porcine bladder acellular matrix been
treated with VEGF-NPs-F127 gel by multipoint sequential injection.
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tified and optimized to obtain the preferred particle size,
entrapment, and polydispersibility of the VEGF-NPs sys-
tem. Then, the thermo-sensitive behavior was proven by
the in vitro and in vivo study, and the kinetic sustained
release profile of the VEGF-NPs-F127 gel system
embedded in porcine bladder acellular matrix was inves-
tigated. Results indicate that the thermal responsive
VEGF-NPs-F127 gel system prevents acute tissue reac-
tion, inflammation, and toxic manifestation because the
gel creates a tissue-compatible environment and an
effective VEGF sustained release approach. The pro-
posed system provides a promising way for deficient
bladder reconstruction therapy. Entrapment of growth
factor drugs into this kind of nanohydrogels for deficient
bladder reconstruction therapy will form the scope of
our future study.
Authors’ contributions section
Hongquan Geng and Hua Song prepared the NPs-
embedded thermo-sensitive hydrogel. Hongquan Geng
characterized NPs and determined the encapsulation eff-
ciency. Hua Song studied the in vitro drug release, fluor-
e s c e n c ei m a g eo ft h em i c ew i t hQ D s - N P s - F 1 2 7g e l ,
determined the bioactivity of released VEGF and drafted
the manuscript. Jun Qi and Daxiang Cui conceived of
the study, and participated in its design and revised the
manuscript.
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PBS at pH 7.4 and 37°C.
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